Literature DB >> 29084293

Recent development of risk-prediction models for incident hypertension: An updated systematic review.

Dongdong Sun1,2, Jielin Liu1,2, Lei Xiao3, Ya Liu1,2, Zuoguang Wang1,2, Chuang Li1,2, Yongxin Jin1,2, Qiong Zhao4, Shaojun Wen1,2.   

Abstract

BACKGROUND: Hypertension is a leading global health threat and a major cardiovascular disease. Since clinical interventions are effective in delaying the disease progression from prehypertension to hypertension, diagnostic prediction models to identify patient populations at high risk for hypertension are imperative.
METHODS: Both PubMed and Embase databases were searched for eligible reports of either prediction models or risk scores of hypertension. The study data were collected, including risk factors, statistic methods, characteristics of study design and participants, performance measurement, etc.
RESULTS: From the searched literature, 26 studies reporting 48 prediction models were selected. Among them, 20 reports studied the established models using traditional risk factors, such as body mass index (BMI), age, smoking, blood pressure (BP) level, parental history of hypertension, and biochemical factors, whereas 6 reports used genetic risk score (GRS) as the prediction factor. AUC ranged from 0.64 to 0.97, and C-statistic ranged from 60% to 90%.
CONCLUSIONS: The traditional models are still the predominant risk prediction models for hypertension, but recently, more models have begun to incorporate genetic factors as part of their model predictors. However, these genetic predictors need to be well selected. The current reported models have acceptable to good discrimination and calibration ability, but whether the models can be applied in clinical practice still needs more validation and adjustment.

Entities:  

Mesh:

Year:  2017        PMID: 29084293      PMCID: PMC5662179          DOI: 10.1371/journal.pone.0187240

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

The number of people living with hypertension is predicted to be 1.56 billion worldwide by the year 2025[1]. In addition, hypertension contributes to ~13% of the total mortality worldwide[2] and ~7% of the total disability-adjusted life years, creating a tremendous financial burden for both patients and the health-care system[2]. The association between hypertension and traditional risk factors such as age, body mass index (BMI), blood pressure (BP), smoking and family history have been well studied, whereas the roles of genetic variants associated with the incidence of hypertension are less clearly defined[3,4]. In 2013, Echouffo-Tcheugui JB et al. published a systematic review of 11 articles with 15 models[5]. Most of these models were carried out in Caucasian populations, and the prediction factors used in these studies were almost identical. Noticeably, none of the above models took genetic factors into consideration, whereas in recent years, more study designs of hypertension risk prediction models have tended not only to have larger patient enrollment size with diverse ethnic backgrounds but also to include genetic factors in these models. Therefore, we conducted this systematic review to summarize the current development status and performance of hypertension prediction models, which would provide updates for health-care providers and policy-makers in the field of hypertension research and clinical practice. This review could also help improve hypertension awareness, identify populations at high risk for hypertension, and determine those individuals who could benefit from early interventions.

Method

Search strategy

The research strategy, study selection and analysis methods used in this study followed the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement[6] (S1 Table). We conducted a complete literature search in both PubMed and Embase to retrieve all published reports about hypertension prediction models using the keywords “hypertension”, “high blood pressure”, “prediction model”, and “risk score”. The search strategy was (((prediction model[Title/Abstract]) OR risk score)) AND ((hypertension[Title/Abstract]) OR high blood pressure[Title/Abstract]). The last search was conducted on September 5, 2016. The related references from those retrieved reports were also searched manually to identify any additional published reports. For those identified articles that were not available online, we contacted the authors directly to request copies.

Inclusion and exclusion criteria

All the retrieved reports were screened independently for inclusion by two researchers from this study. The titles and abstracts of retrieved papers were used as the primary review content for inclusion verification. However, if questioned or unclear, the full article was reviewed prior to inclusion decision. The study’s inclusion criteria include: 1. Reporting a risk assessment tool, e.g., an equation or a risk score system; 2. Predicting the risk incidence of essential hypertension; 3. Published in English-language journals; 4. Conducted in subjects 18 years old or older; 5. Reporting quantitative measures of model performance (preferred but not necessarily required). Exclusion criteria include: 1. Studies only describe association between risk factors and incident hypertension; 2. Simulation studies; 3. Studies predict gestation-related hypertension; 4. Unpublished research data.

Data extraction and synthesis

Any discrepancy of the independently collected data from the two researchers was resolved by group discussion among all participating project investigators. The following data were extracted from each study: study design, subject characteristics, number of subjects in derivation and validation cohorts, number of subjects who developed hypertension, number of candidate variables considered, variables included in the final model and statistical method used for development of the model. We extracted the area under the curve (AUC) of the receiver operating characteristic or C-statistic to assess the discrimination ability of each model. We also collected the value of Hosmer–Lemeshow χ2, and the p value of the corresponding test statistic, to assess model calibration ability. Due to the wide spread of differences in risk factors, population, study design, and sufficiency of data, it was impossible to perform meta-analysis in our current study. Instead, we opted to conduct a narrative synthesis of the evidence. However, to provide a nice summary graph, we applied the random effects model meta-analysis to combine the estimates of the AUC from studies with enough data and assessed the between-study heterogeneity, with the use of the Stata statistical software version 12.0(http://www.stata.com/). The data used in meta-analysis was transformed in the way of double arcsine transformations to addresses the problems of confidence limits and variance instability. The potential publication bias was assessed with funnel plot, as well as Begg's and Egger’s test. A P value <.05 indicated significant publication bias.

Results

The process of the literature search and paper selection, according to PRISMA guidelines, is presented in Fig 1. Our initial literature search resulted in 7332 citations; only 26 articles were selected, reporting 48 prediction models. Table 1 shows the characteristics of these 26 studies, of which 5 were conducted in the US[7-11], 5 in Europe[12-16], 7 in China[17-23], 4 in Korea[24-27], 2 in Japan[28,29], 2 in Iran[30,31], and 1 in India[32]. Among them, only 1 study was carried out in women alone[9]. A total of 162,358 subjects were enrolled in these studies. In the longitudinal studies, participants were followed up for 3 to 30 years. The definition of hypertension among these studies was consistent. Twenty-four studies defined hypertension as either systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg, or the use of antihypertensive drugs. Two studies[17,31] defined isolated systolic hypertension as SBP ≥140 mmHg and DBP ≤ 90 mmHg, and isolated diastolic hypertension as DBP ≥ 90 mmHg and SBP ≤ 140 mmHg. Twenty studies used traditional factors only, and 6 studies[11,14,16,19,21,26] also included Genetic Risk Score (GRS) factors (indeed, 2 studies[19,26] used genetic risk factors exclusively). The common predictors included in most models were age, gender, BMI, SBP, DBP, and parental history of hypertension. The SNPs that were used for setting up the GRS system were nearly all derived from the genome-wide association study (GWAS). The number of SNPs used in these studies ranged from 2 to 32 (S2 Table). The AUC or C-statistic of models[11,21] including GRS were superior compared to those without GRS (C-index change = 0.3%–0.5%; p<0.05). Twelve studies proposed to build models with logistic regression, 7 with COX regression, 6 with Weibull regression, and 1 with linear regression.
Fig 1

The process of article search and selection.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Iterns for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/joumal.pmed1000097. For more information, visit www.prisma-statement.org.

Table 1

Characteristics of included articles.

First authorYearCountry/EthnicityStudy designOutcomes/totalAgeDefinition of hypertensionFollow up (years)Type of statistic
Pearson1990USA/Mixed, mainly WhitesProspective104/113025 or lessSelf-reported use of BP lowering medications c30Cox regression analysis
Chih-Jung Yeh2001China/Taiwanprospective87/2373≥20SBP≥ 140 mmHg and DBP< 90 mmHg bc3.23Cox regression analysis
Nisha I. Parikh2008American/whitesprospective796/171720 to 69JNC—VII definition bd4Weibull regression model
Nina P. Paynter2009American/mainly whitesprospectivederivation 1935/9427; validation 1068/539545 and older, females onlySelf-report or SBP≥140 mmHg or DBP≥90 mmHgac8Logistic regression
Mika Kivimäki2009England/mainly whitesprospective1258/820735 to 68JNC—VII definition b5Weibull regerssion
Mika Kivimäki2010England/mainly whitesprospective cohortderivation 614/4135; validation 438/278535 to 68JNC—VII definition b5Weibull regression
Abhijit V. Kshirsagar2010American/whitesprospective3795/1140745 to 64JNC—VII definition c9multiple logistic regression
Mohammadreza Bozorgmanesh2011Iran/Asiansprospective805/465642the average of two DBP measurements≥90 mmHg or the average of two SBP ≥140 mmHg or taking antihypertension medication bc6Weibull proportional hazard regression models
K-L Chien2011China/Taiwanprospective1029/2506≥35JNC—VII definition b6.15multivariate Weibull model
Cristiano Fava2013Sweden/whitesprospectiveNR/10781NRJNC—VII definition b23Multiple linear and logistic regression
Nam-Kyoo Lim2013Korean/Asiansprospective819/474740 to 69JNC—VII definition bc4Weibull regression analysis
Henry2013Northeast Germany/whitesprospectivetraining set 166/803; validation set 157/80220–79SBP/DBP≥140/90 mmHg b5Bayesian networks
Li Guoqi2014China/Asiansprospective1776/389935–64nr15logistic regression
Yun-Hee Choi2014Mexican Americansprospectivenr/443nrJNC—VII definitionnrgeneralized estimating equations method
Yue Qi2014China/Asianscase control1009 with hypertension; 756 normotensive controlscase cohort 64.48±8.53; control 64.23±10.13JNC—VII definition anrlogistic regression
Bum Ju Lee2014Korea/Asianscross-sectional1278921–85SBP/DBP≥140/90 mmHg or physician-diagnosed hypertensionnrcorrelation-based feature selection
Nam-Kyoo Lim2015Korean/Asiansprospectivenr/563240 to 69 yearsJNC—VII definition bc4logistic regression
Toshiaki Otsuka2015Japan/Asiansprospective1633/1502538.8±8.9JNC—VII definition b4Cox proportional hazards model
Xiangfeng Lu2015China/Asiansprospective2559/772435 to 74JNC—VII definition ac7.9logistic regression
Wenchao Zhang2015China/Asiansprospective3793/1747118 to 88JNC—VII definition bc5Cox proportional hazards regression model
Minoru Yamakado2015Japan/Asiansprospective424/263755.2JNC—VII definition d4logistic regression analysis
Joung-Won Lee2015Korea/Asiansprospective2128 men and 2326 women40–69JNC—VII definition ad4Cox proportional hazard model
Samaneh Asgari2015Tehran/Asiansprospective235/4574≥20SBP≥140 mmHg and DBP<90 mmHg bd9.57Cox proportional hazard regression
Samaneh Asgari2015Tehran/Asiansprospective470/4809≥20SBP<140 mmHg and DBP ≥90 mmHg bd9.62Cox proportional hazard regression
Thirunavukkarasu Sathish2016India/blacksprospective70/29715–64JNC—VII definition b7.1logistic regression model
Teemu J. Niiranen2016Finland/whitesprospectivenr/2045≥30JNC—VII definition bc11Multiple linear and logistic regression
Chen, Y.2016China/Chineseprospective2785/1249740.84±11.34JNC—VII definition bc4multivariable backward Cox analyses

Study design is prospective study or cross-sectional study; Outcomes/total means the number of incident hypertension and the total number of participants of each study; Age is expressed as the mean value or range; BP is blood pressure, SBP means systolic blood pressure and DBP means diastolic blood pressure; JNC—VII definition means the definition of hypertension is based on the Joint National Committee (JNC)—VII definition of hypertension (i.e., SBP/DBP ≥140/90 mmHg or use of antihypertension medications).

a means one-time BP measurement was used to define hypertension;

b for average of multiple BP measurements;

c means patient reported anti-hypertensive drugs;

d for abstracted from chart;

First author and year represent study.

The process of article search and selection.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Iterns for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/joumal.pmed1000097. For more information, visit www.prisma-statement.org. Study design is prospective study or cross-sectional study; Outcomes/total means the number of incident hypertension and the total number of participants of each study; Age is expressed as the mean value or range; BP is blood pressure, SBP means systolic blood pressure and DBP means diastolic blood pressure; JNC—VII definition means the definition of hypertension is based on the Joint National Committee (JNC)—VII definition of hypertension (i.e., SBP/DBP ≥140/90 mmHg or use of antihypertension medications). a means one-time BP measurement was used to define hypertension; b for average of multiple BP measurements; c means patient reported anti-hypertensive drugs; d for abstracted from chart; First author and year represent study.

Performance of prediction models

The performance of prediction models is shown in Table 2. AUC ranged from 0.64 to 0.97, and C-statistic ranged from 60% to 90%. The results of pooling 35 models in meta-analysis(S1 File) show the value of AUC as 0.767, 95%CI(0.742, 0.792). The calibration was assessed by Hosmer–Lemeshow χ2, suggesting that these models had good calibration ability.
Table 2

Characteristics of prediction models.

First authorYearModel nameCandidate variables (n)Variables includeAUC/C-statisticCalibrationMethod of validation
Pearson1990Johns HopkinsNRAge, SBP at baseline, paternal history of hypertension and BMINRNRNR
Chih-Jung Yeh2001ISH risk prediction modelNRage, DM, and fibrinogen concentration in men, and age and APTT (activated partial thromboplastin time) in womenNRNRNR
Chih-Jung Yeh2001IDH risk prediction modelNRelevated BMI, glucose concentration, and uric acid concentration were significant factors in men; BMI was the only significant factor in women.NRNRNR
Nisha I. Parikh2008Framingham risk score11age, sex, SBP, DBP, BMI, parental hypertension, and cigarette smokingNR/0.788,95% CI(0.733, 0.803)Hosmer–Lemeshow χ2 = 4.35NR
Nina P. Paynter2009WHS inclusive risk prediction14age, BP, BMI, total grain intake, apolipoprotein B, ethnicity, lipoprotein(a), C-reactive proteinNR/0.705Hosmer–Lemeshow χ2 = 2.9(P = 0.94)Internal validation, split-sample 2:1
Nina P. Paynter2009WHS Simplified Model with Lipids23Age, BMI, SBP, DBP, ethnicity (Black or Hispanic) and total to HDL- cholesterol ratioNR/0.705Hosmer-Lemeshow χ2 = 9.4(P = 0.31)Internal validation, split-sample 2:1
Nina P. Paynter2009WHS Simplified Model23Age, BMI, race/ethnicity, SBP, and DBPNR/0.703Hosmer–Lemeshow χ2 = 6.0(P = 0.64)Internal validation, split-sample 2:1
Mika Kivimäki2009Whitehall II risk scoreNRAge, sex, SBP, DBP, BMI, parental hypertension and cigarette smokingNR/0.80Hosmer–Lemeshow χ2 = 11.5(<20)Internal validation, split-sample (6:4)
Mika Kivimäki2010Whitehall II Repeat measures risk scoreNRrepeat measures of BP, weight and height, current cigarette smoking and parental history of hypertensionNR/0.799predicted-to-observed ratio 0.98, 95% CI(0.89, 1.08). Hosmer–Lemeshow χ2 = 6.5Internal validation, split-sample
Mika Kivimäki2010the average blood pressure risk scoreNRaverage BP, weight and height, current cigarette smoking and parental history of hypertensionNR/0.794predicted-to-observed ratio 0.96, 95%CI (0.88, 1.06)Internal validation, split-sample
Mika Kivimäki2010the ‘usual’ blood pressure risk scoreNRthe ‘usual’ BP, weight and height, cigarette smoking and parental history of hypertensionNRNRInternal validation, split-sample
Abhijit V. Kshirsagar2010ARIC/CHC risk score11Age, level of SBP or DBP, smoking, family history of hypertension, diabetes mellitus, high BMI, female sex, and lack of exercise0.739 (3years), 0.755 (6 years), 0.800 (9 years) and 0.782 (ever)/nrNRInternal validation, split-sample
Mohammadreza Bozorgmanesh2011TLGS risk multivariable modelsNRfor women: age, waist circumference, DBP, SBP, and family history of premature CVD; for men: age, DBP, SBP, and smoking; for both: the interaction terms between age and SBP, Increasing levels of SBPNR/0.731 (95% CI 0.706–0.755) for women; 0.741 (95% CI 0.719–0.763) for menwomen (Hosmer–Lemeshow χ2 = 7.8, P = 0.554) and men (Hosmer–Lemeshow χ2 = 8.8, P = 0.452).NR
Mohammadreza Bozorgmanesh2011TLGS risk scoreNRWaist circumference, DBP, family history of premature cardiovascular disease, daily smoking, SBPNR/0.727 (95% CI 0.709–0.744)NRNR
K-L Chien2011Taiwan BP clinical risk modelNRgender, age, BMI, SBP and DBP0.732,95% CI (0.712,0.752)/NRHosmer–Lemeshow χ2 = 8.3, p = 0.40NR
K-L Chien2011Taiwan BP clinical risk modelNRgender, age, BMI, SBP and DBP, white blood count, fasting glucose and uric acid0.735,95% CI (0.715–0.755)/NRHosmer–Lemeshow χ2 = 13.2, p = 0.11NR
Cristiano Fava2013Swedish nongenetic risk modelNRage, sex, age2, sex times age, heart rate, obesity, diabetes, hypertriglyceridemia, prehypertension, family history of hypertension, sedentary in spare time, problematic alcohol behavior, married or living as a couple, high-level non-manual work, smokingNR/0.662NRNR
Cristiano Fava2013Swedish genetic risk model2929 SNPsNRNRNR
Cristiano Fava2013Swedish risk model 2NRage, sex, age2, sex times age, heart rate, obesity, diabetes, hypertriglyceridemia, prehypertension, family history of hypertension, sedentary in spare time, problematic alcohol behavior, married or living as a couple, high-level non-manual work, smoking, 29 SNPsNR/0.664NRNR
Nam-Kyoo Lim2013KoGES risk scoreNRage, sex, smoking, SBP, DBP, parental hypertension, BMI0.79,95% CI (0.764,0.815) /NRχ2 = 13.42, P = 0.0981NR
Henry2013SHIP risk model42age, mean arterial pressure, rs16998073, serum glucose and urinary albumin concentrations, interaction between age and serum glucose, interaction between rs16998073 and urinary albumin concentrationstraining set 0.78 95% CI(0.74,0.82); validation set 0.79,95%CI (0.75,0.83)/NRHosmer–Lemeshow χ2 = 11.82 (P = 0.16) for training set; 11.65 (P = 0.17) for the validation setInternal (1:1) and external validation
Yue Qi2014northeastern Han Chinese genetic risk score109 SNPsNRNRNR
Bum Ju Lee2014Demographic indices risk prediction model1 for women41Height, Age, NeckC, AxillaryC, RibC, WaistC, PelvicC, Rib_Hip, Waist_Hip, Pelvic_Hip, Rib_Pelvic, Axillary_Rib, Chest_Rib, Axillary_Chest, Forehead_Neck0.696 for Bayes-correlation-based feature selection;0.713 for logistic regression-correlation-based feature selection/NRNRNR
Bum Ju Lee2014Demographic indices risk prediction model2 for women41Height, Age, ForeheadC, NeckC, HipC, Axillary_Hip, Axillary_Pelvic, Chest_Pelvic, Chest_Rib0.713/NRNRNR
Bum Ju Lee2014Demographic indices risk prediction model3 for women41Height, Weight, BMI, Age, ChestC, Forehead_Hip, Waist_Hip, Chest_Pelvic, Waist_Pelvic, Axillary_Waist, Forehead_Rib, Neck_Axillary0.721/NRNRNR
Bum Ju Lee2014Demographic indices risk prediction model 1 for men41Age, ForeheadC, NeckC, AxillaryC, ChestC, RibC, WaistC, PelvicC, HipC, Rib_Hip, Waist_Hip, Rib_Pelvic, Waist_Pelvic, Chest_Waist, Forehead_Rib, Chest_Rib, Axillary_Chest, Forehead_Neck0.64 for Bayes-correlation-based feature selection and 0.637 for logistic regression-correlation-based feature selection/nrNRNR
Bum Ju Lee2014Demographic indices risk prediction model 2 for men41Height, Age, ForeheadC, NeckC, AxillaryC, HipC, Rib_Hip, Pelvic_Hip, Neck_Pelvic, Waist_Pelvic, Chest_Waist, Chest_Rib, Neck_Chest, Axillary_Chest, Forehead_Neck0.646/NRNRNR
Bum Ju Lee2014Demographic indices risk prediction model 3 for women41Height, ForeheadC, NeckC, AxillaryC, RibC, PelvicC, Forehead_Hip, Chest_Hip, Rib_Hip, Pelvic_Hip, Forehead_Waist, Axillary_Waist, Rib_Waist, Neck_Rib, Axillary_Rib, Chest_Rib, Forehead_Axillary, Forehead_Neck, WHtR0.652/NRNRNR
Li Guoqi2014China risk prediction model 1NRage, SBP, DBP, BMI and the history of parental hypertensionNR/0.7168Hosmer-Lemeshow χ2 = 3.75NR
Li Guoqi2014China risk prediction model 2NRAge, SBP, DBP, BMI and the history of parental hypertension, TG, HDL-CNR/0.7208Hosmer-Lemeshow χ2 = 3.10NR
Li Guoqi2014China risk prediction scoreNRAge, SBP, DBP, BMI and the history of parental hypertensionNRNRNR
Yun-Hee Choi2014marginal modelNRIntercept, Age, Gender, Smoke, Age×gender, Rs10510257 (AA), Rs10510257 (AG), Rs1047115 (GT)0.839/NRNRNR
Yun-Hee Choi2014conditional modelNRIntercept, Age, Gender, Smoke, Age×gender, Rs10510257 (AA), Rs10510257 (AG), Rs1047115 (GT)0.973/NRNRNR
Xiangfeng Lu2015InterASIA risk predictionNRModel1: Age, sex, and BMI; Model2: Model 1+smoking, drinking, pulse rate, and education; Model3: Model2 + SBP and DBPNR/Model1:0.650 (0.637–0.663); Model2:0.683 (0.670–0.695);Model3:0.774 (0.763–0.785)NRNR
Wenchao Zhang2015biomarker-based risk-prediction model11inflammatory factor, blood viscidity factor, insulin resistance factor, blood pressure factor, and lipid resistance factor75.5% for men and 80.1% for women/nrNRNR
Nam-Kyoo Lim2015Korean genetic risk score4rs995322, rs17249754, rs1378942, rs12945290NRNRinternal validation fivefold cross-validation
Minoru Yamakado2015the PFAA index19PFAA index 1, Leucine, Alanine, Tyrosine, asparagine, tryptophan, and Glycine; PFAA index 2, Isoleucine, Alanine, Tyrosine, phenylalanine, methionine and histidineNRNRNR
Toshiaki Otsuka2015Japanese risk prediction modelNRage, BMI, SBP and DBP, current smoking status, excessive alcohol intake, parental history of hypertensionNR/0.861, 95% CI(0.844, 0.877)Hosmer–Lemeshow χ2 = 15.2 P = 0.085 in validation cohortinternal validation Split-sample (80% vs.20%)
Toshiaki Otsuka2015Japanese risk score sheetNRage, BMI, SBP and DBP, current smoking status, excessive alcohol intake and parental history of hypertensionNR/0.858, 95% CI(0.840,0.876)Hosmer–Lemeshow χ2 = 9.3 P = 0.41 in validation cohortinternal validation Split-sample (80% vs.20%)
Joung-Won Lee2015Anthropometric indices risk predictionNRBMI; WaistC; waist-to-hip ratio; waist-to-height ratioNRNRNR
Samaneh Asgari2015TLGS risk prediction for ISH17Age, SBP, BMI, 2 hours post-challenge plasma glucoseNR/0.91NRNR
Samaneh Asgari2015TLGS risk prediction for IDH17Age, DBP, waist circumference, marital status, gender, HDL-CNR/0.76NRNR
Thirunavukkarasu Sathish2016rural India risk score11age, sex, years of schooling, daily intake of fruits or vegetables, current smoking, alcohol use, BP, prehypertension, central obesity, history of high blood glucose0.802, 95% CI(0.748–0.856)/NRHosmer-Lemeshow P = 0.940NR
Teemu J. Niiranen2016genetic risk prediction model13232 SNPsNRNRNR
Teemu J. Niiranen2016genetic risk prediction model232model 1 + age + sexNRNRNR
Teemu J. Niiranen2016genetic risk prediction model332model 2 + smoking, diabetes, education, hypercholesterolemia, exercise and BMINR/0.803NRNR
Chen, Y.2016Prediction for men20Age, BMI, SBP, DBP, gamma-glutamyl transferase, fasting blood glucose, Drinking, Age by BMI, Age by DBP0.761, 95% CI(0.752–0.771)NRNR
Chen, Y.2016Prediction for women20Age, BMI, SBP, DBP, fasting blood glucose, total cholesterol, neutrophil granulocyte, Drinking, Smoking0.753, 95% CI(0.741–0.765)NRNR

NR means not reported; BP is blood pressure, SBP is systolic blood pressure and DBP is diastolic blood pressure; BMI is body mass index; AUC means the area under the receiver operating characteristic curve; CI means confidence interval; SNP is single nucleotide polymorphism; NeckC is Neck circumference; AxillaryC: Axillary circumference; RibC: Rib circumference; WaistC: Waist circumference; PelvicC: Pelvic circumference; Rib_Hip: Rib-to-pelvic circumference ratio; Waist_Hip: Waist-to-hip circumference ratio; Pelvic_Hip: Pelvic-to-hip circumference ratio; Rib_Pelvic: Rib-to-pelvic circumference ratio; Axillary_Rib: Axillary-to-rib circumference ratio; Chest_Rib: Chest-to-rib circumference ratio; Axillary_Chest: Axillary-to-chest circumference ratio; Forehead_Neck: Forehead-to-neck circumference ratio; WHtR: Waist-to-height circumference ratio.

NR means not reported; BP is blood pressure, SBP is systolic blood pressure and DBP is diastolic blood pressure; BMI is body mass index; AUC means the area under the receiver operating characteristic curve; CI means confidence interval; SNP is single nucleotide polymorphism; NeckC is Neck circumference; AxillaryC: Axillary circumference; RibC: Rib circumference; WaistC: Waist circumference; PelvicC: Pelvic circumference; Rib_Hip: Rib-to-pelvic circumference ratio; Waist_Hip: Waist-to-hip circumference ratio; Pelvic_Hip: Pelvic-to-hip circumference ratio; Rib_Pelvic: Rib-to-pelvic circumference ratio; Axillary_Rib: Axillary-to-rib circumference ratio; Chest_Rib: Chest-to-rib circumference ratio; Axillary_Chest: Axillary-to-chest circumference ratio; Forehead_Neck: Forehead-to-neck circumference ratio; WHtR: Waist-to-height circumference ratio.

Validation of prediction models

The prediction models of 7 studies[9,10,12,13,15,26,28] were validated in internal cohorts through split samples, with C-statistics ranging from 0.79 to 0.9. Three models were externally validated. The SHIP risk model[15] from northeast Germany was validated by data from the Danish INTER99, comprising 2887 participants, and it performed well, with an AUC of 0.77 (P = 0.74) and the Hosmer–Lemeshow χ2 test of 40.6 (P = 2×10−6). The KoGES risk score from Korea was externally validated by a large nationwide Korean cohort[33]. The discrimination (AUC = 0.733) and calibration (Hosmer–Lemeshow χ2 = 14.85, P = 0.062) of this model were both good. The Framingham model was externally validated by 7 studies[12,15,24,33-36] from different countries (S3 Table).

Meta-analysis

Results from pooling 35 models in the meta-analysis showed that the AUC was 0.767, 95% CI(0.742, 0.792) indicating the performance of prediction models was well. Fig 2 shows the forest plots of analysis. As expected, the heterogeneity between studies(I-squared = 99.5%, Estimate of between-study variance Tau-squared = 0.0055) was significant(S1 file). Publication bias was evaluated with Funnel plot (Fig 3). The results(P>0.05) indicated no significant publication bias.
Fig 2

Forest plots of pooling 35 models.

Fig 3

Funnel plot of publication bias.

Discussion

This systematic review summarizes the current evidence regarding risk models developed to predict incident hypertension. The prediction models could help identify individuals who are more susceptible to hypertension and prioritize the underlying risk factors that lead to the incidence of hypertension. In addition, it could also help individuals with high risk for hypertension and health-care providers to take preventive interventions earlier.

Population of studies

Most of these models were derived from American, European or East Asian populations; only one study was carried out in India, and the other 2 were in Iran. It is perceivable that systematic underestimation or overestimation of risk may occur when applying a model constructed from one particular cohort to a distinct ethnic population with different characteristics (the selection of predictors and the genetic background). We found that most prediction models were established in developed countries, and only a few were established in developing or undeveloped countries. Thus, it is imperative to establish reliable predictive models in those countries or regions to help reduce the incidence of hypertension and cardiovascular events caused by high blood pressure.

Predictors included

The most commonly used predictors include age, BMI, SBP, DBP, etc., which are easy to obtain in clinical practice. A few studies also take blood biochemistry factors or anthropometric parameters[25,27] as predictors (Table 2), which are also part of the routine lab test results in a general physical examination. The biochemistry factors used as predictors include blood glucose, triglycerides, high-density lipoprotein cholesterol (HDL-C), and fibrinogen. It has been reported that the level of blood glucose is associated with high blood pressure[37]. Triglyceride, cholesterol and HDL-C are also known to contribute to blood hyperviscosity[38] and vascular sclerosis, which could lead to the rise of the BP. Since hypertension is also considered as a metabolic disease, the changes of blood biochemical factors could provide important and valuable information for the accuracy of certain hypertension prediction models. It is well known that the interaction between environmental and genetic factors contributes to the development of hypertension. Theoretically, the prediction models should contain both environmental and genetic predictors. Most of the SNPs used to construct GRS were from GWAS (S2 Table). In the Finnish study[16], results showed that GRS were significantly associated with BP but weakly associated with BP increase and incident hypertension; in contrast, in Hispanic Americans[11], GRS was constructed by 2 SNPs on chromosome 3 alone, and when GRS was added into the model, the improvement of predicting capability measured by the AUC was minor. In a Korean population[26], GRS was constructed by 4 SNPs based on GWAS, which was independently associated with the risk of incident hypertension. Among the 4 SNPs, rs17249754 was the same predictor as that selected in 2 Chinese genetic studies[19,21], and rs1378942 was the same as that used in the Swedish genetic study[14]. However, adding GRS into models with traditional risk factors did not significantly improve the discrimination ability. In the Swedish study[14], when adding cGRS (derived from a simple, unweighted count method) into the traditional model, AUC was marginally, but not significantly, improved (from 0.662 to 0.664). In the 29 SNPs that constructed cGRS, one (rs1378942) was the same as that selected in Korean study[26] and two (rs16998073, rs11191548) were the same as those selected in 2 Chinese studies[19,21]. A couple of factors may contribute to these unfavorable observations. First, since hypertension is a known multigene disease, a limited number of SNPs as representative predictors may not fully reflect the overall contribution and weight of all genetic variants. Second, it is possible that some of those included SNPs were selected without fully considering their potential interactions with other genetic variants or environmental factors. In contrast, in a Chinese study[21], adding GRS constructed by 22 carefully selected SNPs to the traditional predictors produced an ideal result, as the C-index value improved significantly (C-index change = 0.3%–0.5%; all p < 0.05). Among the 22 uncorrelated (r2 < 0.5) SNPs, 10 were associated with SBP or DBP from published GWAS data obtained from an East Asian population, and 19 SNPs had been identified and verified in a Chinese population. These results clearly suggested that the contribution and value of GRS to a hypertension prediction model heavily depends on the selection of SNPs. Since hypertension is a disease of polygenic inheritance, the selection of SNPs used for GRS construction is thus critical. Using GWAS results as the only source for SNP selection is inadequate, as the characteristics of SNPs obtained from one particular GWAS may not necessarily be suitable for other ethnic populations. More appropriate SNP selection should come from the genetic research results in the same ethnic group. Other SNP selection considerations for GRS construction should include a sufficient number of SNPs, causal relationship between the select genes and disease development, gene-gene or gene-environment interactions, and proper statistical methods to include or exclude gene loci. At the present stage, genetic markers for predicting hypertension can be of great interest for researchers and basic scientists (and possibly for drug companies), but may not hold much interest for patients. Once genetic factors are included in prediction models, patients cannot use the model for self-assessment, clinicians could face problems explaining the model, and cost for genetic tests can be high. These problems may be resolved with the development of gene-function and gene-sequencing research.

Model validation

Seven studies validated their prediction models using internal validation. All studies indicated good discriminatory ability and calibration, suggesting that the models could be applied in the original population with satisfactory performance. A Framingham prediction model was validated in external populations by 7 studies (S3 Table). It performed well in a study of African-American and Caucasians in the US[35], a German study[15] and a British study[12]. In a large nationwide Korean cohort,[33]the AUC was acceptable, but this model underestimated hypertension incidence (p<0.001) in Korea. In the Multi-Ethnic Study of Atherosclerosis (MESA)[34], including Caucasian, African-American, Hispanic, and Asian (primarily of Chinese descent) participants, the Framingham model showed better discrimination ability than SBP alone or age-specific DBP categories. However, the difference between the observed and the predicted hypertension risks (Hosmer-Lemeshow goodness of fit p<0.001) in the MESA study was significant. In contrast, the discrimination (C-statistics = 0.5 to 0.6) and calibration ability (p<0.0001) in rural Chinese was poor[36], whereas poor agreement (χ2 = 29.73, p = 0.0002) underestimated the risk of hypertension in Koreans[24]. The distinct performance in different populations was partially attributed to the various levels of risk predictors and inherited variables. These differences suggested that a model derived from one particular population could not be directly applied to a distinct population, and the fittest model for one particular population is that derived from the same population.

Heterogeneity

The meta-analysis showed the heterogeneity was significant. The included variables, study designs, number of participants, populations, statistical methods, and follow-up times were different from each other, which might be the source of heterogeneity. We attribute this to the specialization of prediction models, which need to be built for various populations, because no one model could be applied to all people.

Clinical implications

Currently, a large issue regarding hypertension prediction models/scores is that nobody uses these scores in daily life or clinical practice beyond research publications. Some people even question whether hypertension needs to be predicted, as it can be easily measured with noninvasive, cheap, and accessible methods. The function of these models is not only to predict the occurrence of hypertension but, more meaningfully, to remind patients and physicians to pay attention to BP. What is more, it has been proved that the process of progression from normotensive or prehypertension to hypertension can be delayed or prevented by proper and timely clinical interventions. It is urgent and meaningful for people to conduct timely interventions. The importance of prediction models/scores needs to be widely disseminated by authorities or the media to promote their application.

Strengths and limitations of existing models

Most of the current predictors are data commonly collected in routine clinical practice, which are relatively easier for both health-care providers and patients to access. Some models are in the form of risk scores, which may still have room to improve but are also convenient to use in routine clinical practice. Furthermore, several models took GRS into account, which could contribute significantly to their prediction accuracy of hypertension. Since the performance of all these prediction models was accepted as good, the application of these models in clinical practice is very promising. In contrast, several limitations of these prediction models are also noted. First, since not all these studies were specifically designed or conducted for generating prediction models, the clinical data collection may not be complete, and quality of data collected to inform these models also varies greatly; thus, prediction accuracy is a concern. Second, the enrollment number of participants was low in some studies and may not represent the true characteristics of the general population. Third, the various levels of risk predictors and inherited variables between populations made the models inapplicable for other general people. Fourth, a justified method in selecting the suitable SNPs is lacking. Fifth, since most of the BP data were obtained in hospital or clinic settings, the “white coat effect” may influence the outcome of the BP measurement. Sixthly, none of these models have been shown to improve outcomes in prospective research. Lastly, only a few models were indeed validated by internal cohorts, and only 3 were validated in external cohorts. The validation in internal cohort is more or less considered as a repeat of the original cohort and thus may be overoptimistic in its prediction performance results.

Conclusion

Recently, more and more hypertension prediction models have been reported in different countries and among various ethnic populations. Most of the reported predictors are commonly used in routine clinical practice, and the role of genetic factors is earning more attention. However, the incorporation of genetic variation does not improve the performance significantly for all models. The selection of gene loci is critical, and a justified method in selecting the suitable SNPs is needed. The current reported models have satisfying discrimination and calibration ability, but the validation of these models is still insufficient, which is a critical and required step prior to their broad application in daily clinical practice.

Perspective of future research

It is obvious that the current prediction models might not be perfect, but they do provide a solid foundation for future studies. Of course, more studies on prediction models of hypertension should be conducted with large enrollment numbers, complete data collection, experienced or well-trained investigators, and appropriate statistical analysis. With the development of genetic research, more hypertension-associated SNPs will be found, and a standard protocol in gene loci selection as a candidate prediction factor will be needed. Indeed, before any models are used as guidelines, they need to be validated in various cohorts and adjusted accordingly.

Begg’s and Egger’s publication bias plot.

(TIF) Click here for additional data file.

PRISMA 2009 checklist.

(DOC) Click here for additional data file.

SNPs of GRS.

SNP: single nucleotide polymorphism; GWAS: Genome Wide Association Study; NR: not reported. Rs1378942 was chosen in both Sweden and Korean studies; rs17249754 in Korean and 2 Chinese studies; rs11191548 and rs16998073 from Sweden were the same in two Chinese studies; in two Chinese studies, 7 SNPs (rs17030613, rs16849225, rs1173766, rs11066280, rs35444, rs880315 and rs17249754) were the same. (DOCX) Click here for additional data file.

External validation of the Framingham model.

AUC means the area under the receiver operating characteristic curve; CI means confidence interval; JNC—VII definition means the definition of hypertension is based on the Joint National Committee (JNC)—VII definition of hypertension (i.e., SBP/DBP ≥140/90 mmHg or use of antihypertension medications); NR means not reported. First author and year represent study. (DOCX) Click here for additional data file.

Results of meta-analysis and publication bias test.

(DOCX) Click here for additional data file.
  37 in total

1.  Possible role of increased blood viscosity in the hemodynamics of systemic hypertension.

Authors:  R B Devereux; D B Case; M H Alderman; T G Pickering; S Chien; J H Laragh
Journal:  Am J Cardiol       Date:  2000-05-15       Impact factor: 2.778

2.  A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran Lipid and Glucose Study.

Authors:  Mohammadreza Bozorgmanesh; Farzad Hadaegh; Yadollah Mehrabi; Fereidoun Azizi
Journal:  J Hypertens       Date:  2011-08       Impact factor: 4.844

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

4.  Validation of the Korean Genome Epidemiology Study Risk Score to Predict Incident Hypertension in a Large Nationwide Korean Cohort.

Authors:  Nam-Kyoo Lim; Joung-Won Lee; Hyun-Young Park
Journal:  Circ J       Date:  2016-05-25       Impact factor: 2.993

5.  Prediction models for the risk of new-onset hypertension in ethnic Chinese in Taiwan.

Authors:  K-L Chien; H-C Hsu; T-C Su; W-T Chang; F-C Sung; M-F Chen; Y-T Lee
Journal:  J Hum Hypertens       Date:  2010-07-08       Impact factor: 3.012

6.  Incidence and predictors of isolated systolic hypertension and isolated diastolic hypertension in Taiwan.

Authors:  C J Yeh; W H Pan; Y S Jong; Y Y Kuo; C H Lo
Journal:  J Formos Med Assoc       Date:  2001-10       Impact factor: 3.282

7.  Evaluating the Framingham hypertension risk prediction model in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  April P Carson; Cora E Lewis; David R Jacobs; Carmen A Peralta; Lyn M Steffen; Julie K Bower; Sharina D Person; Paul Muntner
Journal:  Hypertension       Date:  2013-09-16       Impact factor: 10.190

8.  Incremental predictive value of adding past blood pressure measurements to the Framingham hypertension risk equation: the Whitehall II Study.

Authors:  Mika Kivimäki; Adam G Tabak; G David Batty; Jane E Ferrie; Hermann Nabi; Michael G Marmot; Daniel R Witte; Archana Singh-Manoux; Martin J Shipley
Journal:  Hypertension       Date:  2010-02-15       Impact factor: 10.190

9.  Prediction of hypertension based on the genetic analysis of longitudinal phenotypes: a comparison of different modeling approaches for the binary trait of hypertension.

Authors:  Yun-Hee Choi; Rafiqul Chowdhury; Balakumar Swaminathan
Journal:  BMC Proc       Date:  2014-06-17

10.  A comparison of the predictive power of anthropometric indices for hypertension and hypotension risk.

Authors:  Bum Ju Lee; Jong Yeol Kim
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more
  24 in total

1.  Development of a risk prediction score for hypertension incidence using Japanese health checkup data.

Authors:  Mariko Kawasoe; Shin Kawasoe; Takuro Kubozono; Satoko Ojima; Takeko Kawabata; Yoshiyuki Ikeda; Naoya Oketani; Hironori Miyahara; Koichi Tokushige; Masaaki Miyata; Mitsuru Ohishi
Journal:  Hypertens Res       Date:  2021-12-27       Impact factor: 5.528

2.  Can risk be predicted? An umbrella systematic review of current risk prediction models for cardiovascular diseases, diabetes and hypertension.

Authors:  Francesca Lucaroni; Domenico Cicciarella Modica; Mattia Macino; Leonardo Palombi; Alessio Abbondanzieri; Giulia Agosti; Giorgia Biondi; Laura Morciano; Antonio Vinci
Journal:  BMJ Open       Date:  2019-12-19       Impact factor: 2.692

3.  Highly precise risk prediction model for new-onset hypertension using artificial intelligence techniques.

Authors:  Hiroshi Kanegae; Kenji Suzuki; Kyohei Fukatani; Tetsuya Ito; Nakahiro Harada; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-09       Impact factor: 3.738

4.  Heritability of blood pressure traits in diverse populations: a systematic review and meta-analysis.

Authors:  Goodarz Kolifarhood; Maryam Daneshpour; Farzad Hadaegh; Siamak Sabour; Hossein Mozafar Saadati; Ali Akbar Haghdoust; Mahdi Akbarzadeh; Bahareh Sedaghati-Khayat; Nasim Khosravi
Journal:  J Hum Hypertens       Date:  2019-09-24       Impact factor: 3.012

5.  Combining population-based administrative health records and electronic medical records for disease surveillance.

Authors:  Saeed Al-Azazi; Alexander Singer; Rasheda Rabbani; Lisa M Lix
Journal:  BMC Med Inform Decis Mak       Date:  2019-07-02       Impact factor: 2.796

6.  Emergence of digital biomarkers to predict and modify treatment efficacy: machine learning study.

Authors:  Nicole L Guthrie; Jason Carpenter; Katherine L Edwards; Kevin J Appelbaum; Sourav Dey; David M Eisenberg; David L Katz; Mark A Berman
Journal:  BMJ Open       Date:  2019-07-23       Impact factor: 2.692

7.  Endothelium-Dependent Vasorelaxant Effect of Prunus Persica Branch on Isolated Rat Thoracic Aorta.

Authors:  Bumjung Kim; Kwang-Woo Kim; Somin Lee; Cheolmin Jo; Kyungjin Lee; Inhye Ham; Ho-Young Choi
Journal:  Nutrients       Date:  2019-08-06       Impact factor: 5.717

8.  Summarising and synthesising regression coefficients through systematic review and meta-analysis for improving hypertension prediction using metamodelling: protocol.

Authors:  Mohammad Ziaul Islam Chowdhury; Iffat Naeem; Hude Quan; Alexander A Leung; Khokan C Sikdar; Maeve O'Beirne; Tanvir C Turin
Journal:  BMJ Open       Date:  2020-04-09       Impact factor: 2.692

9.  Diet-Related Risk Factors for Incident Hypertension During an 11-Year Follow-Up: The Korean Genome Epidemiology Study.

Authors:  Hye Ah Lee; Hyesook Park
Journal:  Nutrients       Date:  2018-08-13       Impact factor: 5.717

10.  Sex-Specific Incidence Rates and Risk Factors for Hypertension During 13 Years of Follow-up: The Tehran Lipid and Glucose Study.

Authors:  Samaneh Asgari; Seyyed Saeed Moazzeni; Fereidoun Azizi; Hengameh Abdi; Davood Khalili; Monir Sadat Hakemi; Farzad Hadaegh
Journal:  Glob Heart       Date:  2020-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.